NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NCT04332653 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
215
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

NeoImmuneTech

Collaborators